Screener
SG&A at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Cost of sales | 4,061 | 3,433 | 6,944 | 5,836 |
| Research and development | 53,890 | 60,471 | 120,155 | 121,206 |
| Selling, general and administrative | 156,896 | 103,851 | 302,252 | 194,511 |
| Total operating expenses | 214,847 | 167,755 | 429,351 | 321,553 |
| Income (loss) from operations | 41,300 | 26,675 | (8,301) | 30,091 |
| Interest and other income | 4,631 | 5,017 | 9,517 | 11,219 |
| Income before income taxes | 45,931 | 31,692 | 1,216 | 41,310 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's SG&A?
- Corcept Therapeutics (CORT) reported SG&A of $156.9M in Q2 2026.
- How has Corcept Therapeutics's SG&A changed year-over-year?
- Corcept Therapeutics's SG&A increased by 51.1% year-over-year, from $103.85M to $156.9M.
- What is the long-term trend for Corcept Therapeutics's SG&A?
- Over 4 years (2021 to 2025), Corcept Therapeutics's SG&A has grown at a 38.4% compound annual growth rate (CAGR), from $122.36M to $448.73M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Corcept Therapeutics's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude